Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares 7-10 Year Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while iShares 7-10 Year Treasury Bond ETF trades at $93.06. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | IEF | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | — |
52-Week High | $29.41 | $97.99 |
52-Week Low | $20.06 | $92.76 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
IEF, an ETF tracking 7-10 year US Treasury bonds, trades at $93.13, up 0.4% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights institutional buying interest amid rising Treasury yields and inflation concerns. The ETF pays regular dividends, with recent distributions around $0.31-$0.32 per share.
The outlook for IEF hinges on interest rate trends and inflation data. Higher yields may pressure prices, but institutional accumulation suggests long-term confidence. Key risks include Fed policy shifts and geopolitical tensions affecting oil prices and bond markets. Investors should weigh yield attractiveness against duration risk in a volatile rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
